The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

被引:4
|
作者
Jirapinyo, Pichamol [1 ,2 ,5 ]
Thompson, Christopher C. [1 ,2 ]
Garcia-Tsao, Guadalupe [3 ,4 ]
Zucker, Stephen D. [1 ,2 ]
Ryou, Marvin [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Yale Sch Med, Sect Digest Dis, New Haven, CT USA
[4] VA CT Healthcare Syst, Sect Digest Dis, West Haven, CT USA
[5] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
关键词
LIFE-STYLE; CIRRHOSIS; FIBROSIS; OBESITY;
D O I
10.1055/a-2146-8857
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG. Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasoundguided PPGmeasurement prior to and at 6months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing . 20% reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis. Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/ m2 (range 30.1.56.7) and 14.7 kPa (range 8.2.36), respectively. At 6 months, median PPG decreased from 5.4mmHg (range 0.7.19.6) to 1.8mmHg (range 0.4.17.6) (P = 0.002), with 79% (11/14) experiencing . 20% reduction. Patients experienced 12.5% (6.5%.26.1%) TWL (P < 0.001) at 6 months, with 89% (17/19) achieving . 7% and 68% (13/19) achieving . 10% TWL. There were significant improvements in noninvasive tests of fibrosis. Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. © 2022 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [11] Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis Sarcopenia and Nonalcoholic Fatty Liver Disease
    Kawaguchi, Takumi
    Takahashi, Hirokazu
    Gerber, Lynn H.
    CLINICS IN LIVER DISEASE, 2023, 27 (02) : 275 - 286
  • [12] The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
    Puri, Puneet
    Sanyal, Arun J.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 121 - +
  • [13] Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease
    Bassegoda, Octavi
    Olivas, Pol
    Turco, Laura
    Mandorfer, Mattias
    Serra-Burriel, Miquel
    Tellez, Luis
    Kwanten, Wilhelmus
    Laroyenne, Alexia
    Farcau, Oana
    Alvarado, Edilmar
    Moga, Lucile
    Vuille-Lessard, Elise
    Fortea, Jose Ignacio
    Ibanez, Luis
    Tosetti, Giulia
    Vanwolleghem, Thomas
    Larrue, Helene
    Burgos-Santamaria, Diego
    Stefanescu, Horia
    Paternostro, Rafael
    Cippitelli, Annalisa
    Lens, Sabela
    Augustin, Salvador
    Llop, Elba
    Laleman, Wim
    Trebicka, Jonel
    Chang, Johannes
    Masnou, Helena
    Zipprich, Alexander
    Miceli, Francesca
    Semmler, Georg
    Forns, Xavier
    Primignani, Massimo
    Banares, Rafael
    Puente, Angela
    Berzigotti, Annalisa
    Rautou, Pierre Emmanuel
    Villanueva, Candid
    Gines, Pere
    Garcia-Pagan, J. C.
    Procopet, Bogdan
    Bureau, Cristophe
    Albillos, Agustin
    Francque, Sven
    Reiberger, Thomas
    Schepis, Filippo
    Graupera, Isabel
    Hernandez-Gea, Virginia
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2276 - +
  • [14] Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
    Pons, Monica
    Augustin, Salvador
    Scheiner, Bernhard
    Guillaume, Maeva
    Rosselli, Matteo
    Rodrigues, Susana G.
    Stefanescu, Horia
    Ma, Mang M.
    Mandorfer, Mattias
    Mergeay-Fabre, Mayka
    Procopet, Bogdan
    Schwabl, Philipp
    Ferlitsch, Arnulf
    Semmler, Georg
    Berzigotti, Annalisa
    Tsochatzis, Emmanuel
    Bureau, Christophe
    Reiberger, Thomas
    Bosch, Jaime
    Abraldes, Juan G.
    Genesca, Joan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (04) : 723 - 732
  • [15] Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease br
    Seo, Da Hea
    Suh, Young Ju
    Cho, Yongin
    Ahn, Seong Hee
    Seo, Seongha
    Hong, Seongbin
    Lee, Yong -ho
    Choi, Young Ju
    Lee, Eunjig
    Kim, So Hun
    DIABETES & METABOLISM JOURNAL, 2022, 46 (04) : 630 - 639
  • [16] Nonalcoholic fatty liver disease following liver transplantation
    Satapathy, Sanjaya Kumar
    Nair, Satheesh
    Vanatta, Jason M.
    HEPATOLOGY INTERNATIONAL, 2013, 7 (02) : 400 - 412
  • [17] Nonalcoholic fatty liver disease following liver transplantation
    Sanjaya Kumar Satapathy
    Satheesh Nair
    Jason M. Vanatta
    Hepatology International, 2013, 7 : 400 - 412
  • [18] Pediatric Nonalcoholic Fatty Liver Disease
    Mitsinikos, Tania
    Mrowczynski-Hernandez, Paula
    Kohli, Rohit
    PEDIATRIC CLINICS OF NORTH AMERICA, 2021, 68 (06) : 1309 - 1320
  • [19] Nonalcoholic Fatty Liver Disease in Pediatric Patients
    Sinatra, Frank R.
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2012, 36 : 43S - 48S
  • [20] Hyperferritinemia in patients with nonalcoholic fatty liver disease
    Barros, Raffaelle K.
    Cotrim, Helma Pinchemel
    Daltro, Carla H.
    Oliveira, Yanaihara A.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (03): : 284 - 289